Tagworks Pharmaceuticals Funding Round

6/22/2023

Venture Equity

$65,000,000

Series A

The company intends to use the funds to advance the lead program, a click-cleavable ADC targeting TAG72, into the clinic, and expand the pipeline.

Private & Independent

Biopharmaceutical

Toernooiveld 1
Nijmegen, 6525 ED
NL

We aim to unlock the full potential of powerful systemic therapies to change the standard of care for patients suffering from severe diseases including cancer. Tagworks Pharmaceuticals was built to resolve the challenges of bringing antibody-drug conjugates (ADCs) and other potent therapies into mainstream cancer treatment. We are the pioneers of the technology known as Click-to-Release, and the first company built to utilize this therapeutic approach. Click-to-Release was developed based on the 2022 Nobel Prize winning research of Carolyn Bertozzi, Morten Meldal and Barry Sharpless, as well as on the foundational work of Joseph Fox (University of Delaware). This technology, centered on the use of a selective chemical (click) reaction in the body to release a payload, enables on-target activation of ADCs, masked Immunomodulators and other prodrugs, as well as off-target deactivation of radioimmunotherapies.